
What is ‘Nimbus'? New COVID variant spreading in THESE 14 US states, know symptoms here
Just before the busy summer travel season in the US, a new COVID variant called NB.1.8.1—also known as 'Nimbus'—is quickly spreading across the world. This version of the virus, which is part of the Omicron family, recently caused a rise in cases in parts of Asia. Now, it's responsible for over one-third of all COVID infections in the US, according to new data.
Health officials first found the variant in the US in late March through testing international travelers at airports. Since then, it's been spotted in over a dozen states, and numbers are expected to grow.
On May 23, the World Health Organization called NB.1.8.1 a 'variant under monitoring' because of how fast it's spreading and changes in its spike protein that could affect how easily it spreads. The nickname 'Nimbus' was given in late May on X by Canadian evolutionary biologist T. Ryan Gregory, who also came up with names for other COVID variants like the 'FLiRT' strains.
While this variant is making up more cases in the US, overall COVID numbers haven't changed much. As of June 7, the test positivity rate was 3%, which is just a 0.2% increase from the previous week. Hospital stays for COVID are actually going down, according to the CDC. Their wastewater tracking, as of June 6, also shows a low level of virus activity across the country.
Still, experts believe this could shift in the next few months. Every summer since 2020 has brought a jump in COVID cases in the US, and the arrival of this new variant has many keeping an eye out for another rise.
Also Read: COVID horror: Over 300 people in US still dying from coronavirus every week, Here's why
Between May 25 and June 7, NB.1.8.1 was responsible for about 37% of COVID cases in the US, up from 15% in the previous two weeks. The top variant at the moment, LP.8.1, is causing 38% of infections.
However, the CDC said its ability to track exact numbers is 'low' because not enough virus samples are being sequenced. The agency hasn't shared regional data yet, but according to sequences posted on the GISAID database, the Nimbus variant has been found in at least 14 states:
• Arizona
• California
• Colorado
• New Jersey
• New York
• Hawaii
• Illinois
• Maryland
• Massachusetts
• Ohio
• Rhode Island
• Vermont
• Virginia
• Washington
Worldwide, the WHO said that as of May 18, NB.1.8.1 had been detected in at least 22 countries and made up about 10.7% of COVID cases.
Experts believe the number of cases caused by this variant will likely continue to rise in the US, based on what's happening in other parts of the world.
The virus behind COVID (SARS-CoV-2) keeps changing. These mutations sometimes help it spread faster or dodge immune protection from past infection or vaccines.
Like other omicron descendants, NB.1.8.1 spreads quickly. It came from a mix of previous variants and has multiple spike protein mutations, which might help it latch onto human cells more effectively. A May study, though not peer-reviewed yet, said these changes could help it spread faster and possibly outcompete other variants in the future.
Based on its makeup and how quickly it's spreading, it's likely that Nimbus is more transmissible than older versions of the virus—but experts say it's too soon to say exactly how it compares.
So far, there's no sign that it causes worse symptoms than other variants. According to the WHO, the overall risk from this variant is still considered 'low.'
It's not yet clear if NB.1.8.1 will become the dominant variant or cause a large summer spike, but experts say it's possible.
'It's hard to predict whether this variant or another will take off and cause a wave … but its likely that it won't be as severe as what we experienced before 2023,' Dr. Albert Ko, professor of public health, epidemiology and medicine at Yale School of Public Health, as cited by Today report.
In the US, most people now have some level of immunity—either from a past infection or vaccination. It's estimated that about 90% of Americans have already been exposed to the virus. But immunity fades over time.
'The longer we get from the last surge or the last vaccination campaign, the more people are susceptible,' Andy Pekosz, Ph.D., professor at Johns Hopkins Bloomberg School of Public Health, previously said.
Add summer travel, big events, and a new variant like Nimbus, and conditions are right for more infections. According to the CDC, COVID tends to peak twice each year in the US—once in winter, and again during summer (June to August). But how big each wave is can vary.
Based on past years, experts expect some increase this summer. 'We may see an upswing (this) summer as in previous years, and this is expected to be smaller compared to what we experience in the winter,' says Ko.
Right now, symptoms from this variant appear similar to other recent omicron strains. These include:
• Sore throat
• Cough
• Runny or stuffy nose
• Trouble breathing
• Fever or chills
• Headache
• Body aches
• Fatigue
• Loss of smell or taste
Anyone can get sick from COVID, but older adults (especially those over 65), people with weakened immune systems, and those with underlying health issues are more likely to get very sick, according to the CDC.
COVID vaccines still help prevent severe illness, hospitalization, and death. With all the changes to vaccine guidance, you might be wondering if you need another dose.
The CDC says the current 2024–2025 COVID vaccines are still available and are recommended for most adults 18 and up.
'Those in high-risk groups should consider getting the vaccine now if they haven't been vaccinated in the last six months and consider receiving an updated vaccine for the upcoming winter season,' says Ko.
WHO also said the current COVID vaccines should still work against NB.1.8.1.
The next round of vaccines for 2025–2026 will be geared toward the LP.8.1 variant and are expected in the fall. But US Health and Human Services Secretary Robert F. Kennedy Jr. recently announced changes that might limit who can get these shots.
Under the new guidelines, the upcoming vaccine will be offered only to adults 65 and older, and to those aged 12–64 with at least one medical condition. Routine COVID vaccines are no longer recommended for healthy children or pregnant women by the CDC, though many doctors disagree.
If you're unsure whether you should get the COVID shot, talk to your healthcare provider.
To stay safe, health officials recommend testing when you feel sick, staying home when you're ill, masking in crowded indoor places, and social distancing. The government no longer mails out free test kits, but some free or low-cost tests are still available.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
25 minutes ago
- Time of India
153% Jump in COVID Searches Reveals India's Vigilance Amid New Wave Fears
New Delhi: As India witnesses a resurgence of COVID-19 cases—with active infections surpassing the 7,000 mark—new search data from local search engine Justdial, reveals a significant shift in public behaviour. COVID-related searches spiked by 153 per cent nationwide between April and May 2025, reflecting a palpable increase in public concern and preparedness across cities. Among the top trends were an 8x increase in searches for government testing centres, a 77 per cent rise in insurance-related queries, and a threefold jump in vaccine centre lookups under the Pradhan Mantri Jan Arogya Yojana (PM-JAY). The capital city Delhi has emerged as the most proactive, with a 140 per cent rise in overall COVID-related searches and a 15x surge in government testing centre queries. According to Justdial's report, the renewed public interest spans both metros and smaller cities, indicating broader health awareness. In Mumbai, searches for private testing rose alongside a 26 per cent increase in insurance-related lookups. Kerala, meanwhile, recorded an 84 per cent surge in insurance searches, the highest in the country. ETHealthworld's Rashmi Kaur spoke to experts from healthcare facilities to understand on how they view the public's proactive approach. 'Yes, we are witnessing huge spikes in footfalls for COVID testing, especially for travelers and those with mild symptoms,' confirmed Dr. Diksha Goyal, Senior Consultant – Internal Medicine at Marengo Asia Hospitals, Gurugram. 'We've streamlined testing logistics, stocked up on kits and PPE, and trained our staff to handle the surge efficiently. Online bookings and electronic reporting are helping us reduce crowding and waiting times.' Dr. Deepak Sanghavi, Vice President of Operations at Agilus Diagnostics, emphasized that the rising interest in testing is not just reactive but also preventive. 'While there's no panic, people are clearly more alert. We're seeing increased demand from symptomatic individuals, their contacts, and even post-infection follow-ups—many opting for home sample collection,' he said. While numbers are rising, doctors believe the clinical picture is changing. 'Many cases are now presenting with milder, influenza-like symptoms such as nasal congestion, sore throat, and fatigue,' said Dr. Goyal. 'Severe respiratory distress is rare, particularly in vaccinated individuals. However, early detection remains tricky, as the symptoms are more insidious. High-risk groups still need close monitoring and timely care.' Dr. Sanghavi echoed, 'This is not the same panic-driven atmosphere we saw during earlier waves. Public behaviour now shows a desire for early awareness and informed action. That's a good sign.' Demand for Booster shots With immunity waning and infection trends climbing, public interest in booster doses is seeing a revival. 'There's a clear uptick in people—especially seniors—seeking booster shots. While national advisories are awaited, state-level initiatives are encouraging precautionary vaccination for high-risk groups,' said Dr. Goyal. What sets this surge apart from earlier waves is the public's proactive response—seeking out information, verifying coverage options, and opting for safe testing methods like home collection. 'Healthcare providers and diagnostics labs are more prepared than ever before,' said Dr. Sanghavi. 'India's healthcare infrastructure, bolstered by earlier experiences, is well-equipped to manage this rise efficiently.' While health authorities monitor the evolving situation, experts agree that public vigilance, timely testing, accurate information, and vaccinations remain the most effective tools in preventing another full-blown crisis.


Time of India
an hour ago
- Time of India
DGCA: No major safety concerns found in Air India's Boeing 787 fleet after enhanced checks
File photo NEW DELHI: India's aviation regulator, the Directorate General of Civil Aviation (DGCA), has completed a focused review of Air India 's Boeing 787 Dreamliner fleet, amid rising concerns over recurring technical issues and increasing international flight volumes post Ahmedabad crash. In a meeting held with key executives from Air India and Air India Express, the DGCA reviewed the operational robustness of the carriers, with particular attention to the Boeing 787 aircraft, which form the backbone of Air India's long-haul network. While recent weeks have seen a spate of long-haul cancellations and flight disruptions, many involving the Dreamliner, the DGCA clarified that enhanced surveillance checks conducted on the 787 fleet revealed no major safety concerns. 'A total of 24 Boeing 787 aircraft underwent required safety inspections. All were found compliant with existing aviation safety standards,' the regulator said in a statement. However, the DGCA flagged maintenance-related issues, particularly around the availability of spare parts and internal coordination between engineering, ground handling, and operations teams. The regulator advised Air India to strengthen these areas to minimise flight delays and improve reliability. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Upto 15% Discount for Salaried Individuals ICICI Pru Life Insurance Plan Get Quote Undo Despite confirming the fleet's airworthiness, the DGCA's review underscores the growing pressure on Air India to scale up international operations without compromising operational consistency. The Boeing 787 Dreamliner is central to Air India's global ambitions, operating on key routes to Europe, North America, and Southeast Asia. As flight volumes surge post-Covid, ensuring the aircraft remain operationally sound is critical to the airline's turnaround strategy under the Tata Group. Air India has not yet issued a statement following the DGCA's advisory. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now


Time of India
2 hours ago
- Time of India
Two more Covid-linked deaths reported in Maharashtra
Mumbai: On Tuesday, the state health department linked two more deaths to Covid-19. One was a 68-year-old woman from Thane with interstitial lung disease, and the other was an 81-year-old man from Solapur with viral meningitis. There were a total of 31 deaths linked to Covid-19 since May. Of these, six were in Mumbai, one of which was just a day earlier in a 44-year-old woman with chronic liver cirrhosis. All the deceased had severe comorbidities. Doctors earlier told TOI that while Covid-19 is not seen to cause mortality by itself, it can pressure and weaken the body further if the person has a severe underlying disease. The cause of deaths in such cases is the primary disease of the person. Meanwhile, the state recorded 67 new cases on Tuesday, of which 17 were in Mumbai. Other cases were reported from Pune (18), Solapur (16), Kolhapur (4), Chhatrapati Sambhajinagar (3), Nagpur (3), Navi Mumbai (2), Thane (2), Pimpri-Chinchwad (1), Kalyan (1), Raigad (1), and Panvel (1). Health officials said all diagnosed patients had mild symptoms.